Evidence map›Paper›PMID 32469985›Full record

Trial reportPloS one2020

Virologic response to efavirenz-based first-line antiretroviral therapy in children with previous exposure to antiretrovirals to prevent mother-to-child transmission.

Patience Nyakato, Mary-Ann Davies, Karl-Gunter Technau, Geoffrey Fatti, Helena Rabie, Frank Tanser, Andrew Boulle, Robin Wood, Brian Eley, Shobna Sawry and 5 more

Open access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 3 countries.

Patience NyakatoCenter for Infectious Diseases Epidemiology and Research, School of Public Health an Family Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, Western Cape, South Africa.ORCID 0000-0002-8418-8500
Mary-Ann DaviesCenter for Infectious Diseases Epidemiology and Research, School of Public Health an Family Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, Western Cape, South Africa.
Karl-Gunter TechnauEmpilweni Services and Research Unit, Department of Paediatrics and Child Health, University of the Witwatersrand, Johannesburg, South Africa.
Geoffrey FattiKheth'Impilo AIDS Free Living, Cape Town, Western Cape, South Africa.
Helena RabieUniversity of Stellenbosch, Stellenbosch, Cape Town, Western Cape, South Africa.
Frank TanserAfrica Health Research Institute, KwaZulu-Natal, Durban, South Africa.
Andrew BoulleCenter for Infectious Diseases Epidemiology and Research, School of Public Health an Family Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, Western Cape, South Africa.
Robin WoodCenter for Infectious Diseases Epidemiology and Research, School of Public Health an Family Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, Western Cape, South Africa.
Brian EleyRed Cross War Memorial Children's Hospital, Cape Town, Western Cape, South Africa.
Shobna SawryWits Reproductive Health and HIV Institute (Wits RHI), Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Janet GiddyMcCord Hospital, Durban, South Africa.
Nosisa SipamboDepartment of Paediatrics and Child Health, Chris Hani Baragwanath Academic Hospital, University of Witwatersrand, Johannesburg, South Africa.
Louise KuhnGertrude H Sergievsky Center, College of Physicians and Surgeons and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, United States of America.
Lee FairlieWits Reproductive Health and HIV Institute (Wits RHI), Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
International epidemiology Database to Evaluate AIDS-Southern Africa (IeDEA-SA) Collaboration
University of Cape Town · ZAUniversity of the Witwatersrand · ZAWestern Cape Department of Health · ZACentre for the AIDS Programme of Research in South Africa · ZAChris Hani Baragwanath Hospital · ZAColumbia University · USMcCord Hospital · ZAStellenbosch University · ZA

Funding

Observational Antiretroviral Studies In Southern Africa (OASIS) CollaborationU01AI069924 · NIAID · UNIVERSITAT BERN · PI Cleophas Chimbetete, Mary-Ann Davies · 2006 to 2026
$55.9M
NIAID NIH HHS U01 AI069924
6 · The paper itself

Abstract

Efavirenz-based first-line regimens have been widely used for children ≥3 years of age starting antiretroviral therapy, despite possible resistance with prior exposure to non-nucleoside reverse transcriptase inhibitors for prevention of mother-to-child transmission (PMTCT). We used logistic regression to examine the association between PMTCT exposure and viral failure (VF) defined as two consecutive viral loads (VL)>1000 copies/ml between 6-18 months on ART. Children with previous nevirapine exposure for PMTCT were not at higher risk of VF compared to unexposed children (adjusted Odds Ratio (aOR): 0.79; 95% CI:0.56, 1.11).

Indexed as

HIV-1HIV InfectionsAdolescentAdultAlkynesAnti-Retroviral AgentsBenzoxazinesChildChild, PreschoolCyclopropanesFemaleHumansInfectious Disease Transmission, VerticalMaleRisk FactorsAlkynesAnti-Retroviral AgentsBenzoxazinesCyclopropanesefavirenz

Identifiers

PMID32469985
PMCPMC7259572
OpenAlexW3028698724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.